Skip to main content

Table 1 Baseline characteristics, cardiovascular risk factors, prior cardiovascular diseases, revascularisations and medications in the protocol and non-protocol treated groups

From: Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction

  Protocol Non-protocol p
n = 99 n = 291
Mean age, years, mean (SD) 59.5 (14) 66.1 (14) <0.001
Age > 75 years, n (%) 11 (11.1) 97 (33.3) <0.001
Male sex, n (%) 74 (74.7) 198 (68.0) 0.210
Diabetes, n (%) 13 (13.1) 64 (22.0) 0.056
Current smoker, n (%) 50 (50.5) 95 (32.6) 0.001
Hypertension, n (%) 49 (49.5) 158 (54.3) 0.408
Dyslipidaemia, n (%) 39 (39.4) 123 (42.3) 0.616
Renal dysfunctiona, n (%) 3 (3.0) 11 (3.8) 0.729
Peripheral vascular disease, n (%) 4 (4.0) 14 (4.8) 0.752
Previous myocardial infarction, n (%) 9 (9.1) 32 (11.0) 0.593
Previous stroke, n (%) 4 (4.0) 21 (7.2) 0.265
Previous CABG, n (%) 1 (1.0) 15 (5.2) 0.073
Previous PCI, n (%) 10 (10.1) 39 (13.4) 0.392
Aspirin, n (%) 21 (21.2) 81 (27.8) 0.195
P2Y12-receptor inhibitor, n (%) 2 (2.0) 11 (3.8) 0.399
Warfarin, n (%) 2 (2.0) 37 (12.7) 0.002
  1. CABG coronary artery by-pass intervention, PCI percutaneous coronary intervention
  2. aestimated glomerular filtration rate <60 ml/min/1.73 m2